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Targeting FLT3 in primary MLL-gene–rearranged infant acute
lymphoblastic leukemia
Ronald W. Stam, Monique L. den Boer, Pauline Schneider, Peter Nollau, Martin Horstmann, H. Berna Beverloo, Ella van der Voort,
Maria G. Valsecchi, Paola de Lorenzo, Stephen E. Sallan, Scott A. Armstrong, and Rob Pieters
Acute lymphoblastic leukemia (ALL) in
infants is characterized by rearrange-
ments of the mixed lineage leukemia
(MLL) gene, drug resistance, and a poor
treatment outcome. Therefore, novel
therapeutic strategies are needed to im-
prove prognosis. Recently, we showed
that FLT3 is highly expressed in MLL
rearranged ALL (MLL). Here we demon-
strate FLT3 expression in infants with
MLL (n  41) to be significantly higher
compared to both infant (n  8; P < .001)
and noninfant patients with ALL (n  23;
P  .001) carrying germline MLL genes.
Furthermore, leukemic cells from infants
with MLL were significantly more sensi-
tive to the Fms-like tyrosine kinase 3
(FLT3) inhibitor PKC412 (N-benzoyl stau-
rosporine) than noninfant ALL cells, and
at least as sensitive as internal tandem
duplication-positive (ITD) AML cells. Sur-
prisingly, activation loop mutations only
occurred in about 3% (1 of 36) of the
cases and no FLT3/ITDs were observed.
However, measuring FLT3 phosphoryla-
tion in infants with MLL expressing vary-
ing levels of wild-type FLT3 revealed that
high-level FLT3 expression is associated
with ligand-independent FLT3 activation.
This suggests that infant MLL cells dis-
playing activated FLT3 as a result of over-
expression can be targeted by FLT3 inhibi-
tors such as PKC412. However, at
concentrations of PKC412 minimally re-
quired to fully inhibit FLT3 phosphoryla-
tion, the cytotoxic effects were only frac-
tional. Thus, PKC412-induced apoptosis
in infant MLL cells is unlikely to be a
consequence of FLT3 inhibition alone but
may involve inhibition of multiple other
kinases by this drug. (Blood. 2005;106:
2484-2490)
© 2005 by The American Society of Hematology
Introduction
Translocations involving the mixed lineage leukemia (MLL, HRX,
or ALL1) gene on chromosome band 11q23 are most frequently
found in acute lymphoblastic leukemia (ALL) in infants ( 1 year
of age), with an incidence as high as about 80%.1,2 The presence of
MLL gene rearrangements is an independent prognostic factor for
an adverse outcome.2-5 Hence, the prognosis for infant ALL is
exceedingly poor with an event-free survival (EFS) of approxi-
mately 35%.6 This poor treatment outcome is largely due to cellular
drug resistance. Leukemic cells from infants with ALL are
significantly more resistant to most chemotherapeutic drugs both in
vitro and in vivo, as compared to cells from older children with
ALL.7-9 This is especially true for prednisolone and L-asparaginase.
Because the clinical outcome for infants with ALL bearing
germline MLL genes appears to be much more favorable,9-11 novel
therapeutic targets specific for MLL-gene–rearranged infant ALL
(infant MLL) are urgently needed.
In search for suitable targets, we recently compared gene
expression profiles from MLL-gene–rearranged ALL patients with
profiles from both ALL and acute myeloid leukemia (AML)
patients carrying germline MLL genes. This study demonstrated
that MLL-gene–rearranged ALL is characterized by high-level
expression of the gene encoding Fms-like tyrosine kinase 3 (FLT3,
STK-1, FLK-2, or CD135).12 FLT3 is a membrane-bound receptor
for the hematopoietic growth factor FLT3 ligand (FLT3L or FL)
and is important in early hematopoietic development.13 On binding
of FLT3L, wild-type FLT3 receptors dimerize and become acti-
vated by phosphorylation, positively affecting several signal trans-
duction pathways all of which favor cell survival and prolifera-
tion.14 In the absence of ligand binding, FLT3 only has minimal
kinase activity as a consequence of auto-inhibition by the juxtamem-
brane (JM) domain of the receptor.15
With an incidence of approximately 30%, FLT3 is the most
frequently mutated gene in AML.16 Mutations in FLT3 appear to
activate the receptor in a ligand-independent manner, constitutively
promoting proliferation and survival, thus providing the leukemic
cell with a growth advantage and transforming capacity. Distinct
types of such activating mutations within 2 separate regions of the
FLT3 gene have been described. The first are in-frame internal
tandem duplications (ITDs) within the JM domain-coding se-
quence of FLT3.17 These FLT3/ITDs disrupt the auto-inhibitory
activity of the JM domain, leading to receptor dimerization and
subsequent auto-phosphorylation in the absence of FLT3L.18 The
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second type of activating mutations affect either Asp835 or Ile836
within the second tyrosine kinase domain of the FLT3 receptor. At
first, point mutations were described that resulted in alternative
amino acids at Asp835.19 Recently, insertions after Asp835 as well
as deletions of the adjacent codon Ile836 (836) have been
reported.20,21 Analogous to point mutations at Asp816 within a
corresponding domain of the receptor tyrosine kinase c-KIT,22
these mutations alter the conformation of the activation loop from
an inactive to an active state, allowing auto-phosphorylation and
thus activation of FLT3 again in the absence of its ligand.14
The identification of activating mutations and their high inci-
dence in patients with AML have led to the development of several
small-molecule inhibitors to selectively target the constitutive
FLT3 signal, inducing leukemic cells to undergo programmed cell
death (apoptosis). The potential of several FLT3 inhibitors as
therapeutic drugs has been or is currently being tested in phase 1/2
clinical trials in adults with relapsed or refractory AML or
myelodysplastic syndromes (MDS).23-27 Recently we found the
staurosporine derivative PKC412 (N-benzoyl staurosporine), a
known inhibitor of FLT3,28 to be cytotoxic to acute lymphoblastic
leukemia cell lines carrying translocations involving MLL and
activated FLT3 receptors as a consequence of either mutation or
overexpression of wild-type FLT3.21 Moreover, PKC412 also
appeared to be active in vivo, efficiently targeting human MLL
rearranged ALL cells overexpressing wild-type FLT3, in mice.21
The present study was designed to explore FLT3 as a therapeutic
target in primary patient samples from infants with MLL. There-
fore, we measured FLT3 as well as FLT3L mRNA expression levels
in a large cohort of infants with MLL and compared these to the
expression levels of these genes in both infants and older children
(noninfants) with ALL carrying germline MLL genes. Additionally,
the cytotoxic effects of PKC412 were determined in primary infant
MLL and noninfant ALL samples. Finally, we assessed the infant
MLL samples for the presence of activating mutations in FLT3 and
analyzed the level of FLT3 receptor phosphorylation in patients
carrying either mutated or wild-type FLT3.
Patients, materials, and methods
Patient samples
Primary bone marrow or peripheral-blood samples from untreated infants
( 1 year of age) initially diagnosed with ALL were collected at the
Erasmus Medical Center (MC)/Sophia Children’s Hospital and other
hospitals participating in the INTERFANT-99 treatment study. Samples
from pediatric ALL patients older than 1 year of age were obtained either
from the German Cooperative ALL (COALL) study group or the Erasmus
MC/Sophia Children’s Hospital. Approval was obtained from the Erasmus
MC Institutional Review Board for these studies. Informed consent was
provided according to the Declaration of Helsinki. Within 24 hours after
sampling, mononuclear cells were isolated by density gradient centrifuga-
tion using Lymphoprep (density 1.077 g/mL; Nycomed Pharma, Oslo,
Norway), centrifuged at 480g for 15 minutes at room temperature. Isolated
mononuclear cells were washed twice in phosphate-buffered saline (PBS)
and resuspended in RPMI 1640 medium (Dutch modification without
L-glutamine; Invitrogen Life Technologies, Breda, The Netherlands)
supplemented with 20% fetal calf serum (FCS; Integro, Zaandam, The
Netherlands), 2 mM L-glutamine (Invitrogen Life Technologies), 5
g/mL insulin, 5 g/mL transferrin, 5 ng/mL sodium selenite (ITS
media supplement; Sigma, St Louis, MO), 100 IU/mL penicillin, 100
g/mL streptomycin, 0.125 g/mL amphotericin B, and 0.2 mg/mL
gentamicin (Invitrogen Life Technologies). Contaminating nonleukemic
cells were removed using immunomagnetic beads as described by
Kaspers et al.29 All samples used contained more than 90% leukemic
cells, as determined morphologically on cytospins stained with May-
Gru¨nwald-Giemsa stain (Merck, Darmstadt, Germany).
Patient characteristics were collected in reference laboratories of the
INTERFANT-99 and the COALL study groups. As part of the INTER-
FANT-99 study, the infant ALL samples were screened for the presence of
MLL rearrangements by fluorescent in situ hybridization (FISH) analysis,
and the type of translocation determined using polymerase chain reaction
(PCR). In the present study 35% of the infant ALL samples carried a t(4;11),
28.3% a t(11;19), 10% a t(9;11), and 13.3% had germline MLL genes. The
remaining 13.3% of the samples either carried other less frequently found
translocations involving the MLL gene, or PCR analysis could not be
performed due to lack of material.
RNA and DNA extraction
Total RNA and gDNA were extracted from a minimum of 5  106 leukemic
cells using TRIzol reagent (Invitrogen Life Technologies) according to the
manufacturer’s instructions with minor modifications. Quantification of
both RNA and DNA was performed using a spectrophotometer and the
integrity of the extracted RNA was assessed on 1% agarose gels.
Quantitative real-time PCR
Extracted RNA was reverse transcribed and the obtained cDNA was used to
quantify FLT3 and FLT3L mRNA expression relative to the endogenous
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
using quantitative real-time PCR (TaqMan) as described previously.30
Primer and probe combinations used to amplify and detect FLT3, FLT3L
and GAPDH expression are listed in Table 1.
Detection of FLT3/ITDs
Detection of ITDs of the JM domain of FLT3 was performed as described
by Kiyoi et al.31 PCRs were carried out in a total reaction volume of 50 L
containing TaqMan buffer II (Applied Biosystems, Foster City, CA), 2 mM
MgCl2, 200 M of each dNTP (Amersham Pharmacia Biotech, Uppsala,
Sweden), 300 nM forward and reverse primer,31 1.25 U AmpliTaq Gold
DNA polymerase (Applied Biosystems), and 500 ng gDNA as a template.
Samples were heated for 10 minutes at 95°C to activate the AmpliTaq Gold
polymerase and amplified during 40 cycles of 15 seconds at 95°C and 60
seconds at 60°C. gDNA extracted from the MV4-11 cell line, which has
been shown to posses a FLT3/ITD,32 was used a as positive control.
Detection of FLT3 activation-loop mutations
Detection of the activating mutations affecting either Asp835 or Ile836
within the activation loop of the FLT3 gene was performed essentially as
described by Yamamoto et al.19 However, to fit our standard PCR
procedure, a different set of primers (FLT3 forward: 5-TCA CCG GTA
CCT CCT ACT G-3; reverse: ACT G-3, 5-AAA TGC ACC ACA GTG





Forward 5-AGC ATC CCA GTC AAT CAG-3
Reverse 5-CTG GCT GGT GCT TAT GA-3
Probe 5-(FAM)-TTA AAG CCT ACC CAC AAA TCA GAT GT-(TAMRA)-3
FLT3L
Forward 5-GAG CCC AAC AAC CTA TCT C-3
Reverse 5-GGA CGA AGC GAA GAC A-3
Probe 5-(FAM)-ATG GAG CGG CTC AAG ACT GT-(TAMRA)-3
GAPDH
Forward 5-GTC GGA GTC AAC GGA TT-3
Reverse 5-AAG CTT CCC GTT CTC AG-3
Probe 5-(FAM)-TCA ACT ACA TGG TTT ACA TGT TCC AA-(TAMRA)-3
FAM indicates 6-carboxyfluorescein; TAMRA, 6-carboxytetramethyl-rhodamine.
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AGT G-3) was designed to amplify the region of interest. To detect
mutations, PCR products amplified as described (see “Detection of
FLT3/ITDs”), were digested overnight at 37°C using the restriction enzyme
EcoRV. Incomplete digested PCR products, visualized on 2% agarose gels,
were extracted from the gel using the Wizard SV gel and Clean-up system
(Promega, Leiden, The Netherlands). Clean undigested PCR fragments
were cloned into pCR2.1 plasmids using a TA cloning kit (Invitrogen Life
Technologies) and transformed into competent Escherichia coli (DH5)
cells by heat shock. Individual clones were recovered from overnight
cultures using the Wizard Plus SV Minipreps DNA purification system
(Promega) and sequenced on a 310 Genetic Analyzer (Applied Biosystems)
using the BigDye Terminator v1.1 cycle sequencing protocol (Applied
Biosystems) to confirm the presence of a mutation.
Detection of FLT3 gene amplification using FISH analysis
The presence of FLT3 amplification was determined with dual-color FISH
analysis on cytospin preparations. Two BAC clones, 153M24 and 179F17,
isolated from the human Bacteria Artificial Chromosome (BAC) library
RPCI-11 (Children’s Hospital Oakland Research Institute, BACPAC Re-
sources, Oakland, CA), containing FLT3 sequences were used as probes.
Probes were labeled by nick translation using digoxigenin-11-deoxyuridene
triphosphate (dUTP) for 179F17 and biotin-16-dUTP for 153M24 and were
hybridized and detected as previously described.33 The hybridization
mixture contained 50 ng of each labeled probe and 5 g human Cot-1 DNA.
In all cases 2 independent observers examined 100 to 200 nuclei.
In vitro PKC412 cytotoxicity using MTT assay
In vitro cytotoxicity to PKC412 was determined using the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT) assay as
described previously.34 Briefly, leukemic cells were cultured in round-
bottomed 96-well microtiter plates in the presence of 6 concentrations of
PKC412 (N-benzoyl staurosporine; kindly provided by Thomas Meyer,
Novartis Pharma, Basel, Switzerland), with the highest concentration of 10
M and a 3-fold dilution factor. Control cells were cultured in 8 wells in the
absence of PKC412. Four wells containing 100 L culture medium were
used as blanks. After incubating the plates for 4 days at 37°C in humidified
air containing 5% CO2, 10 L MTT, (5 mg/mL; Sigma) was added and the
plates were incubated for an additional 6 hours under the same conditions.
During this final 6-hour incubation, the yellow MTT tetrazolium salt is
reduced to purple-blue formazan crystals by viable cells only. Formazan
crystals were dissolved by adding 100 L acidified isopropanol (0.04 N
HCl-isopropyl alcohol) and the optical density, which is linearly related to
the number of viable cells,35 was measured at 562 nm on a spectrophotom-
eter. Assay results were deemed successful when a minimum of 70%
leukemic cells was present in the control wells after 4 days of incubation
and when the control optical density exceeds 0.050.34
Immunoprecipitation and Western blot analysis
of FLT3 phosphorylation
Leukemic cells were cultured both in the absence and presence of 500 nM
PKC412. After 4 hours of exposure to PKC412, cells were washed twice in
ice-cold PBS and resuspended in 100 L lysis buffer composed of 25 mM
Tris (tris(hydroxymethyl)aminomethane) buffer, 150 mM NaCl, 5 mM
EDTA (ethylenediaminetetraacetic acid), 10% glycerol, 1% Triton X-100,
10 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 10 mM
glycerolphosphate, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfo-
nyl fluoride (PMSF), 1% aprotinin (Sigma), 10 mM sodium fluoride, and
20 L freshly prepared sodium pervanadate. Accordingly, cell lysis was
allowed for 30 minutes on ice. Cell lysates were cleared by centrifuga-
tion for 15 minutes at 10 000 g (13 000 rpm) and 4°C. Protein
concentration was determined using the bicinchoninic acid (BCA)
protein assay (Pierce Biotechnology, Rockford, IL) with different
concentrations of bovine serum albumin (BSA) as standards.
For immunoprecipitation (IP), aliquots of whole cellular lysates contain-
ing 500 g protein were precleared with 10 L G-plus Agarose (Santa Cruz
Biotechnology, Santa Cruz, CA) and accordingly IP was performed with
10 L G-plus Agarose supplemented with 3 g rabbit polyclonal antibodies
specific for the human FLT3 (Santa Cruz Biotechnology). Following
denaturation in Laemmli buffer, precipitates were separated on 4% to 12%
polyacrylamide gradient gels and separated proteins were transferred to
polyvinylidene difluoride (PVDF) membranes on which tyrosine phosphor-
ylation was detected using 4G10 mouse antibodies (Upstate Biotechnology,
Lake Placid, NY) and visualized using peroxidase-labeled secondary rabbit
anti–mouse antibodies and chemiluminescence (ECL kit; Amersham, Little
Chalfont, United Kingdom). To confirm FLT3 receptor expression, blots
were stripped and reprobed with anti–rabbit polyclonal antibodies against
FLT3 (Santa Cruz Biotechnology).
Statistical analysis
Differences in FLT3 and FLT3L expression between patient groups were
statistically evaluated using the Mann-Whitney U test. Differences in mean
cytotoxicity responses between patient groups were statistically analyzed
using the Student t test. All analyses were 2-tailed, and differences were
considered statistically significant at P values of less than .05.
Results
Using quantitative real-time PCR we confirmed our earlier gene
expression profiling data12; elevated FLT3 mRNA expression
levels were detected in MLL-gene–rearranged infant ALL (infant
MLL) as compared to both infants and older children (noninfants)
carrying germline MLL genes (Figure 1A). Infant MLL patients
(n  41) expressed significantly (P  .001) about 16-fold higher
levels of FLT3 mRNA as compared to infant ALL patients (n  8)
and about 2-fold higher than noninfant ALL patients (n  22;
P  .001). No differences in FLT3L expression were observed
between infant MLL (n  33), infant ALL (n  4), and noninfant
ALL (n  10) patients (Figure 1B).
PKC412 has been shown to be cytotoxic to lymphoblastic
leukemia cell lines carrying MLL gene rearrangements.20 In the
present study we investigated the effects of PKC412 on primary
infant MLL cells. In vitro PKC412 cytotoxicity was determined in
Figure 1. Relative FLT3 and FLT3L expression in childhood ALL with and
without MLL gene rearrangements. (A) Relative mRNA expression of the Fms-like
tyrosine kinase 3 (FLT3) as determined by quantitative real-time PCR (TaqMan) in
infants with MLL (n  41) and both infants (n  8) and noninfants (n  22) with ALL
harboring germline MLL genes. (B) Relative FLT3 ligand (FLT3L) expression in
primary infant MLL (n  33), infant ALL (n  4), and noninfant ALL (n  10) samples.
E indicates individual patients; and —, median expression values. Differences in
FLT3 and FLT3L expression between 2 patient groups were statistically analyzed
using the Mann-Whitney U test. NS indicates that P was higher than .05 in all
comparisons.
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29 infant MLL and 19 noninfant ALL patients, as well as in 5 AML
patients carrying FLT3/ITDs. Figure 2A shows the mean cytotoxic
response at 4 increasing concentrations of PKC412. At PKC412
concentrations ranging from 40 to 375 nM, no response is observed
in the noninfant ALL samples, whereas these concentrations of
PKC412 increasingly induced leukemic-cell death in the infant
MLL samples (Figure 2A). The differences in cytotoxic response to
PKC412 between infant MLL and noninfant ALL samples were
statistically significant at PKC412 concentrations of 125 nM and
higher (P  .01). Moreover, the cytotoxic response to PKC412 in
infant MLL was comparable to the response observed in FLT3/
ITD AML samples (Figure 2A). Using the median FLT3 expres-
sion from Figure 1 as the cut-off value, the infant MLL samples for
which both FLT3 expression and PKC412 cytotoxicity data were
obtained were divided into 2 groups expressing either low or high
levels of FLT3 transcripts. As shown in Figure 2B, the cytotoxic
response to PKC412 is more pronounced in infant MLL samples
expressing high FLT3 mRNA levels as compared to infant MLL
samples expressing lower levels of FLT3, although these differ-
ences did not reach statistical significance.
To investigate whether activating mutations in FLT3 could
explain the observed sensitivity to PKC412, we next assessed the
infant MLL samples for the presence of both ITDs within the JM
domain and activation loop mutations affecting either Asp835 or
Ile836. None of the 39 infant MLL samples tested appeared to
exhibit a FLT3/ITD. Figure 3A shows the amplified region
surrounding the FLT3/ITD in MV4;11 cells as a positive control
and 4 examples of FLT3/ITD	 infant MLL patients. Of 36 infant
MLL samples tested only one patient (
3%) harbored a mutation
within the activation loop FLT3. Figure 3B shows incomplete
EcoRV digestion of the amplified region harboring codons Asp835
and Ile836 (encompassing the EcoRV recognition sequence) within
the FLT3 activation loop from this patient. Complete digestion of
this PCR product from a patient sample negative for this type of
mutation is also shown. Sequence analysis of the mutation revealed
that this patient carried a 3-nucleotide (CAT) deletion that results in
a deletion of isoleucine 836 (836), as shown in Figure 3C.
Because the frequency of known activating FLT3 mutations in
our cohort of infant MLL patients appeared to be very low, whereas
the infant MLL cells are more sensitive to the FLT3 inhibitor
PKC412 as compared to leukemic cells from noninfant ALL
patients (Figure 2), we asked whether high-level expression of
FLT3 is sufficient to auto-phosphorylate and thus activate FLT3 in
the absence of activating mutations. To study this, FLT3 phosphor-
ylation was assessed in several infant MLL patients displaying
varying levels of FLT3 expression as well as in a noninfant ALL
patient (Figure 4). The first 3 patients express high levels of
wild-type FLT3 (as determined by sequence analysis of the entire
FLT3 gene) and exhibit significant levels of FLT3 phosphorylation
and thus activation, which was completely reversed on exposure of
the leukemic cells to 500 nM PKC412 for 4 hours (Figure 4A).
Patient no. 4 represents the one infant MLL patient in whom the
836 activation loop mutation was identified. As expected, revers-
ible FLT3 phosphorylation was also detected in this sample (Figure
4A). Patients no. 5 and no. 6 are samples from an infant MLL and a
noninfant ALL patient, respectively, expressing low levels of FLT3
(Figure 4C). No FLT3 phosphorylation could be observed in these
samples (Figure 4A). Figure 4B clearly demonstrates that the
patients expressing high levels of wild-type FLT3 are sensitive to
PKC412, whereas the samples from patients expressing low FLT3
levels that lack FLT3 phosphorylation do not respond to this
drug. Patient no. 4, carrying the 836 activation loop mutation,
seems to respond only at concentrations of PKC412 above
300 nM (Figure 4B).
In the MLL rearranged ALL cell line SEMK2-M1, overexpres-
sion of FLT3 has been shown to be due to amplification of the FLT3
gene on chromosome 13q12.21 To investigate whether gene ampli-
fications of FLT3 also explained high-level FLT3 expression as
observed in primary MLL rearranged ALL cells, we screened
infant MLL (n  39) samples for FLT3 amplifications using
FISH analysis. However, none of the 39 samples tested showed
amplified FLT3.
Discussion
The class 3 receptor tyrosine kinase Fms-like tyrosine kinase 3
(FLT3) is one of the most frequently mutated genes in hematologic
malignancies, including both AML and ALL.14 ITDs of the JM
domain and mutations within the activation loop of the receptor
appeared to constitutively activate the receptor in a ligand-
independent manner, consequently promoting proliferation and
survival.19,31 It was recently shown by microarray analysis that
FLT3 is overexpressed in patients with MLL-gene–rearranged ALL
Figure 2. In vitro PKC412 cytotoxicity in childhood ALL with and without MLL
gene rearrangements. (A) MTT dose-response curves showing the mean cytotoxic
response to PKC412 in primary leukemic cells from infants with MLL (n  29),
noninfants with ALL (n  19), and FLT3/ITD AML patients (n  5). (B) MTT
dose-response curves showing the mean cytotoxic response to PKC412 in infant
MLL samples expressing high levels of FLT3 (n  9) compared to infant MLL samples
expressing lower FLT3 levels (n  8). Error bars represent SEM.
Figure 3. FLT3-activating mutations in infant MLL. (A) ITD of the JM domain of
FLT3 in the MV4-11 cell line (C indicates positive control) and 4 examples of infant
MLL patients negative for FLT3/ITDs as determined by PCR. (B) Amplified PCR
product covering the EcoRV site within the activation loop of FLT3, undigested (U)
and digested in both a patient positive () and negative (	) for this type of mutation.
(C) Sequence analysis of the activation loop mutation found in 1 of 36 patients tested.
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(designated MLL), when compared to patients with both conven-
tional ALL and AML lacking chromosomal abnormalities involv-
ing the MLL gene.12 Furthermore, human leukemia cell lines
carrying chromosomal translocations involving MLL and activated
FLT3 are sensitive to FLT3 inhibition in vitro and in a mouse model
of MLL.21 In the present study, we show that overexpression of
wild-type FLT3 is associated with sensitivity to PKC412 in primary
infant MLL cells.
Using quantitative real-time PCR analysis we confirmed high-
level FLT3 expression in leukemic cells from patients carrying
MLL gene rearrangements as previously shown by gene expression
profiling.12 Infant MLL patients significantly expressed higher
levels of FLT3 mRNA as compared to both infant ALL and
noninfant ALL samples harboring germline MLL genes. Screening
the cohort of infant MLL patients for the presence of described
activating mutations in FLT3, however, showed these mutations to
be extremely rare in this group of patients. Nevertheless, compar-
ing the mean cytotoxic response of the FLT3 inhibitor PKC412 in
leukemic cells from infant MLL and noninfant ALL patients, we
observed that infant MLL patients are markedly more sensitive to
this drug. To evaluate the relative sensitivity of infant MLL samples
to PKC412 with respect to patient samples harboring activating
mutations, we also assessed the cytotoxic response of PKC412 to
several FLT3/ITDAML samples. Infant MLL patients appeared at
least equally as sensitive to PKC412 as AML patients carrying
FLT3/ITDs. Interestingly, infant MLL patients displaying high-
level FLT3 expression tended to be more sensitive to PKC412 as
compared to infant MLL patients expressing lower levels of FLT3,
suggesting a relation between the level of FLT3 expression and
sensitivity to PKC412. In addition, we observed that high-level
FLT3 expression is associated with FLT3 phosphorylation, which
is in concordance with previous data.36 This suggests that high-
level expression of wild-type FLT3 may indeed be sufficient to
activate the receptor in the absence of ligand binding, thereby
sensitizing these leukemic cells to FLT3 inhibition.
The most frequent type of activating mutations found in AML
are FLT3/ITDs, which occur in approximately 24% of the adult
cases and in about 10% to 15% of the childhood cases.14 In adult
ALL, tandem duplications of the JM domain are rarely observed.14
Recently Armstrong et al described novel deletions within a
7-amino acid region of the JM domain of FLT3 in 3 of 25 (12%)
children with hyperdiploid ALL.37 In the present study, no FLT3/
ITDs were observed as primary in infant MLL samples, which is in
concordance with data reported by Xu et al.38 In contrast to MLL
rearranged ALL, FLT3/ITD is rather frequently observed in AML
patients carrying intragenic abnormalities within the MLL gene
such as partial tandem duplications.39,40
In comparison to previously reported frequencies, the incidence
of activation loop mutations in this cohort of infant MLL samples
(
3%) seems rather low. We have previously reported the inci-
dence of activation loop mutations in another group of MLL
samples to be approximately 17% (5 of 30).21 Taketani et al
reported 8 of 44 (
18%) infant MLL cases ( 1 year of age) to
harbor mutations within the activation loop.41 Despite this discrep-
ancy it can be concluded that the incidence of activating mutations
in infant MLL is less than 20% (3%-18%); thus, activating
mutations do not fully explain the relative sensitivity of primary
leukemic cells from infant MLL patients to the FLT3 inhibitor
PKC412. Recently Zheng et al reported evidence that in primary
AML samples expressing both wild-type FLT3 and FLT3L, consti-
tutively activated FLT3 can be detected as a consequence of
autocrine signaling.42 Theoretically, this could sensitize these cells
to FLT3 inhibition, creating the possibility that the sensitivity to
PKC412 as observed in primary infant MLL samples might be
explained by elevated FLT3L expression resulting in increased
ligand-dependent receptor activation. However, we show that
FLT3L expression does not statistically differ between primary
infant MLL, infant ALL, and noninfant ALL samples, suggesting
that it is unlikely that infant MLL cells are more sensitive to
PKC412 than noninfant ALL cells due to elevated autocrine
receptor activation. Therefore, the fact that infant MLL patients
expressing high amounts of wild-type FLT3 mRNA exhibit pro-
nounced levels of phosphorylated FLT3 that was completely
inhibited by 500 nM PKC412 within a 4-hour exposure period,
suggests that indeed overexpression of wild-type FLT3 is sufficient
to activate FLT3 in a ligand-independent manner.
Thus, overexpression of FLT3 identifies groups of patients
sensitive to FLT3 inhibition as is shown in the present study in
infant MLL, as well as previously reported in AML patients.43 The
reason for FLT3 overexpression in MLL patients, however, remains
unclear. One explanation might be that the immunophenotype of
infant ALL cells usually is that of a very immature early B-lineage
Figure 4. Relation between high-level FLT3 expression,
FLT3 activation, and in vitro sensitivity to PKC412. (A)
Immunoprecipitation (IP) analysis of FLT3 in primary infant
MLL cells carrying wild-type (patient nos. 1-3 and 5) or
mutated (patient no. 4) FLT3, cultured for 4 hours in the
absence and presence of 500 nM PCK412. Patient no. 6
represents a noninfantALL patient. To determine the phospho-
tyrosine (pTyr) content of FLT3, immunoblots were probed
with antiphosphotyrosine (4G10) and with anti-FLT3 to as-
sess FLT3 loading. (B) MTT dose-response curves show the
mean cytotoxic response to PKC412 for the individual pa-
tients. Error bars represent SEM of duplicate wells. (C)
Representation of the FLT3 expression levels for the indi-
vidual patients. WB indicates Western blot.
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progenitor in which FLT3 expression has been shown to be the
highest.15,45 Leukemic cells from infant ALL patients carrying
germline MLL genes most often show common or pre-B pheno-
types, expressing lower levels of FLT3. The consistently high
expression of FLT3 specifically in MLL may also suggest that MLL
translocations influence the expression of this gene. In search for a
mechanism by which FLT3 expression is elevated in infant MLL,
we screened 39 infant MLL samples for the presence of FLT3 gene
amplification as found in the MLL rearranged ALL cell line
SEMK2, which expresses exceedingly high levels of wild-type
FLT3.21 However, none of the patient samples appeared to harbor
amplified FLT3, excluding gene amplification as the etiology for
FLT3 overexpression.
After the discovery of the high incidence of activating FLT3
mutations in AML, several small-molecule tyrosine kinase inhibi-
tors were developed to target the constitutive FLT3 signal as a
potentially novel therapeutic drug. The efficacy of several of the
most promising FLT3 inhibitors including PKC412,28 CEP-701,32
and SU541644 is currently being tested in phase 2 clinical trials in
adult AML, and preliminary results are encouraging.23,24,26,27
Interestingly, sensitivity toward these inhibitors seems to vary
between the different types of activating mutations.45 PKC412, a
staurosporine derivative originally identified as a inhibitor of
protein kinase C (PKC),46 has been shown to be effective against
activated FLT3 resulting from both ITD and mutations in the
activation loop of the receptor.45 Moreover, PKC412 has also been
shown to display inhibiting activity against several other class 3
receptor tyrosine kinases such as KDR, c-KIT, and platelet-derived
growth factor receptor (PDGFR).46 In the present study, we
demonstrate that PKC412 exhibits antileukemic activity against
primary infant MLL cells with activated FLT3 receptors, whereas
these effects were not observed in infant MLL cells lacking
activated FLT3. These observations imply that leukemic-cell death
induced on exposure to PKC412 in these cells specifically seems
due to inhibition of FLT3. However, PKC412 has been shown
almost completely inhibit FLT3 phosphorylation at a concentration
of 100 nM.21 Although the present study does show a statistically
significant difference in mean PKC412 cytotoxicity between infant
MLL (
10% leukemic-cell death) and noninfant ALL (no re-
sponse) patients at this dose level, the absolute difference is rather
small. At higher dosages of PKC412 the differences are more
pronounced, and substantial percentages of leukemic-cell death are
observed within the infant MLL patient group. Given that FLT3
activation should fully be inhibited at PKC412 concentrations of
approximately 100 nM, the increasing amounts of cell death as
observed at higher PKC412 concentrations may not specifically be
a consequence of FLT3 inhibition, but may rather be due to
nonspecific inhibition of any of the multiple other kinases inhibited
by PKC412. Therefore, these data suggest that infant MLL samples
are significantly more sensitive to multitarget kinase inhibition that
includes the inhibition of FLT3. Moreover, our data indicate that
FLT3 inhibition alone is not sufficient to induce substantial degrees
of leukemic-cell death in primary leukemia samples, including
ITDAML samples. This latter may suggest that the greater degree
of cytotoxicity that has been reported in similar primary MLL
samples using the FLT3 inhibitor CEP-70136 may be due to
inhibition of additional targets by this agent at concentrations
similar to those required to inhibit FLT3. Nevertheless, initial
results from phase 1/2 clinical trials using PKC412 or CEP-701 as
single agents in refractory adult AML (and MDS) patients show
that both inhibitors exhibit potential clinical activity. PKC412,
administered orally at a dose of 75 mg 3 times daily, decreased
peripheral-blood counts by 50% in 14 of 20 patients (70%).23
CEP-701, given orally at a dose of 60 mg twice daily, significantly
reduced bone marrow and peripheral-blood blasts in 5 of 14
patients (36%).24 Thus, receptor tyrosine kinase inhibition using
small-molecule FLT3 inhibitors may be a potential therapeutic
approach for innovative treatments for MLL-gene–rearranged in-
fant ALL. Based on these findings, a phase 1/2 study using FLT3
inhibitors in childhood leukemia is currently in preparation (R.P.).
Possible strategies are to use FLT3 inhibitors in relapsed MLL or
selected MLL rearranged cases at very high risk of relapse, either as
single agents or in combination with conventional chemotherapeu-
tic drugs, because preclinical studies demonstrating synergistic
effects of FLT3 inhibitors with cytarabine (Ara-C) and daunorubi-
cin have been reported.47
In conclusion, the present study shows that FLT3 expression is
high in leukemic cells from infants with MLL rearranged ALL and
that high FLT3 expression likely is associated with auto-
phosphorylation (activation) of FLT3. Infant MLL samples were
more sensitive to PKC412 than noninfant ALL samples. However,
the concentration of PKC412 required to induce substantial levels
of leukemic-cell death in these samples is higher than the concen-
tration needed to completely inhibit FLT3 phosphorylation. Thus,
PKC412-induced cell death in infant MLL samples likely is a
consequence of multitarget kinase inhibition, including inhibition
of FLT3. Therefore, inclusion of multitarget tyrosine kinase
inhibitors in current treatment regimens may be a potential novel
therapeutic strategy to improve outcome for infant MLL patients.
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